Hongmei Luo , Longzhong Liu , Jiafeng Zou , Jiufeng Zhao , Chengxin Sun , Shuiping Ou , Jianwen Yang
{"title":"Seleromitrion diffusa (Willd).治疗慢性萎缩性胃炎的网络药理学研究","authors":"Hongmei Luo , Longzhong Liu , Jiafeng Zou , Jiufeng Zhao , Chengxin Sun , Shuiping Ou , Jianwen Yang","doi":"10.1016/j.ipha.2023.10.003","DOIUrl":null,"url":null,"abstract":"<div><h3>Objective</h3><p>The study aimed to investigate <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang (HDSB) in the treatment of chronic atrophic gastritis (CAG) by using network pharmacology and literature research.</p></div><div><h3>Methods</h3><p>TCMSP, Uniprot, Drug Bank, OMIM, and GeneCards were used to obtain the active components, targets of <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang and the disease targets of CAG. Cytoscape 3.9.1 was used to construct a drug network. STRING platform was used to analyze the PPI network, and Metascape was used for functional enrichment analysis and KEGG pathway enrichment analysis.</p></div><div><h3>Results</h3><p>The study found a total of 34 active compounds of HDSB, 153 predicted targets, 970 disease targets, and 46 intersection targets of CAG. And identified a total of 27 prescriptions or proprietary Chinese medicines containing <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang through literature research and database search, that consists in a 1:1, 1:2, or 2:1 ratio, with a dose range of 15 g–300 g.</p></div><div><h3>Conclusion</h3><p>The study suggests that <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang may exert therapeutic effects on chronic atrophic gastritis by acting on JNK, PI3K-Akt, HIF-1, cancer-related and others.</p></div>","PeriodicalId":100682,"journal":{"name":"Intelligent Pharmacy","volume":"2 1","pages":"Pages 45-50"},"PeriodicalIF":0.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2949866X23000941/pdfft?md5=0e2cb4654703f8f9c12531a8d9cb34a4&pid=1-s2.0-S2949866X23000941-main.pdf","citationCount":"0","resultStr":"{\"title\":\"Network pharmacology study of Seleromitrion diffusa (Willd). R. J. Wang and Scutellaria barbata D. Don in the treatment of chronic atrophic gastritis\",\"authors\":\"Hongmei Luo , Longzhong Liu , Jiafeng Zou , Jiufeng Zhao , Chengxin Sun , Shuiping Ou , Jianwen Yang\",\"doi\":\"10.1016/j.ipha.2023.10.003\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objective</h3><p>The study aimed to investigate <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang (HDSB) in the treatment of chronic atrophic gastritis (CAG) by using network pharmacology and literature research.</p></div><div><h3>Methods</h3><p>TCMSP, Uniprot, Drug Bank, OMIM, and GeneCards were used to obtain the active components, targets of <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang and the disease targets of CAG. Cytoscape 3.9.1 was used to construct a drug network. STRING platform was used to analyze the PPI network, and Metascape was used for functional enrichment analysis and KEGG pathway enrichment analysis.</p></div><div><h3>Results</h3><p>The study found a total of 34 active compounds of HDSB, 153 predicted targets, 970 disease targets, and 46 intersection targets of CAG. And identified a total of 27 prescriptions or proprietary Chinese medicines containing <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang through literature research and database search, that consists in a 1:1, 1:2, or 2:1 ratio, with a dose range of 15 g–300 g.</p></div><div><h3>Conclusion</h3><p>The study suggests that <em>Scutellaria barbata</em> D. Don and <em>Seleromitrion diffusa</em> (Willd). R. J. Wang may exert therapeutic effects on chronic atrophic gastritis by acting on JNK, PI3K-Akt, HIF-1, cancer-related and others.</p></div>\",\"PeriodicalId\":100682,\"journal\":{\"name\":\"Intelligent Pharmacy\",\"volume\":\"2 1\",\"pages\":\"Pages 45-50\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23000941/pdfft?md5=0e2cb4654703f8f9c12531a8d9cb34a4&pid=1-s2.0-S2949866X23000941-main.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Intelligent Pharmacy\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2949866X23000941\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Intelligent Pharmacy","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2949866X23000941","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
目的 通过网络药理学和文献研究，探讨黄芩（Scutellaria barbata D. Don）和泽泻（Seleromitrion diffusa (Willd).方法利用TCMSP、Uniprot、Drug Bank、OMIM和GeneCards等数据库获得黄芩和Seleromitrion diffusa (Willd)的有效成分、靶点以及慢性萎缩性胃炎（CAG）的疾病靶点。R. J. Wang 和 CAG 的疾病靶标。使用 Cytoscape 3.9.1 构建药物网络。结果该研究共发现了34个HDSB活性化合物、153个预测靶点、970个疾病靶点和46个CAG交叉靶点。并通过文献研究发现了含有黄芩（Scutellaria barbata D. Don）和泽泻（Selleromitrion diffusa (Willd).通过文献研究和数据库检索，共发现 27 个处方或中成药中含有黄芩（Scutellaria barbata D. Don）和泽泻（Seleromitrion diffusa (Willd.)），配比为 1:1、1:2 或 2:1，剂量范围为 15 克-300 克。该研究表明，黄芩（Scutellaria barbata D. Don）和Seleromitrion diffusa（Willd. R. J. Wang）可通过作用于JNK、PI3K-Akt、HIF-1、癌症相关等因子对慢性萎缩性胃炎产生治疗作用。
Network pharmacology study of Seleromitrion diffusa (Willd). R. J. Wang and Scutellaria barbata D. Don in the treatment of chronic atrophic gastritis
Objective
The study aimed to investigate Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang (HDSB) in the treatment of chronic atrophic gastritis (CAG) by using network pharmacology and literature research.
Methods
TCMSP, Uniprot, Drug Bank, OMIM, and GeneCards were used to obtain the active components, targets of Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang and the disease targets of CAG. Cytoscape 3.9.1 was used to construct a drug network. STRING platform was used to analyze the PPI network, and Metascape was used for functional enrichment analysis and KEGG pathway enrichment analysis.
Results
The study found a total of 34 active compounds of HDSB, 153 predicted targets, 970 disease targets, and 46 intersection targets of CAG. And identified a total of 27 prescriptions or proprietary Chinese medicines containing Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang through literature research and database search, that consists in a 1:1, 1:2, or 2:1 ratio, with a dose range of 15 g–300 g.
Conclusion
The study suggests that Scutellaria barbata D. Don and Seleromitrion diffusa (Willd). R. J. Wang may exert therapeutic effects on chronic atrophic gastritis by acting on JNK, PI3K-Akt, HIF-1, cancer-related and others.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
